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4H-1-benzopyran-4-ones  (chromones)  are  important  naturally-distributing  compounds.  As  compared
with  ﬂavones,  isoﬂavones  and  2-styrylchromones,  there  are  only  few  papers  of 3-styrylchromones
that  have  been  published.  We  have  previously  reported  that among  ﬁfteen  3-styrylchromone
derivatives,  three  new  synthetic  compounds  that  have  OCH3 group  at the  C-6  position  of
chromone  ring,  (E)-3-(4-hydroxystyryl)-6-methoxy-4H-chromen-4-one  (compound  11),  (E)-6-methoxy-
3-(4-methoxystyryl)-4H-chromen-4-one  (compound  4),  (E)-6-methoxy-3-(3,4,5-trimethoxystyryl)-4H-
chromen-4-one  (compound  6) showed  much  higher  cytotoxicities  against  four epithelial  human  oral
squamous  cell  carcinoma  (OSCC)  lines than  human  normal  oral  mesenchymal  cells.  In order  to  further
conﬁrm  the  tumor  speciﬁcities  of these  compounds,  we compared  their  cytotoxicities  against  both  human
epithelial  malignant  and  non-malignant  cells,  and  then  investigated  their  effects  on  ﬁne  cell  structures
and  metabolic  proﬁles  and  cell death  in human  OSCC  cell  line  HSC-2.  Cytotoxicities  of compounds  4,
6,  11  were  assayed  with  MTT method.  Fine  cell  structures  were  observed  under  transmission  electron
microscope.  Cellular  metabolites  were  extracted  with  methanol  and subjected  to  CE-TOFMS  analysis.
Compounds  4, 6, 11  showed  much  weaker  cytotoxicity  against  human  oral  keratinocyte  and  primary
human  gingival  epithelial  cells,  as compared  with  HSC-2,  conﬁrming  their  tumor-speciﬁcity,  whereas
doxorubicin  and  5-FU  were  highly  cytotoxic  to these  normal  epithelial  cells,  giving unexpectedly  lower
tumor-speciﬁcity.  The  most cytotoxic  compound  11,  induced  the  mitochondrial  vacuolization,  autophagyeywords:
-Styrylchromones
ytotoxicity
itochondria
etabolomics proﬁling
poptosis
utophagy
suppression  followed  by  apoptosis  induction,  and  changes  in  the  metabolites  involved  in amino  acid  and
glycerophospholipid  metabolisms.  Chemical  modiﬁcation  of  lead  compound  11 may  be a potential  choice
for designing  new  type of  anticancer  drugs.
©  2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction4H-1-benzopyran-4-ones (chromones) are an important class
f oxygenated heterocyclic compounds since the chromone core
tructure is found in ﬂavones, isoﬂavones and 2-styrylchromones.
∗ Corresponding author. Fax: +81 49 285 5171.
E-mail address: sakagami@dent.meikai.ac.jp (H. Sakagami).
ttp://dx.doi.org/10.1016/j.toxrep.2015.09.009
214-7500/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).As compared with ﬂavones and isoﬂavones, 2-styrylchromones
constitute a much smaller group of naturally occurring chromones.
Synthetic 2-styrylchromones showed antioxidant [1], anti-
allergic [2], anti-inﬂammatory [3], antitumor [4–6], and antiviral
[7,8] activities. In contrast, as far as we know there were
only two papers of 3-styrylchromones that investigated the
antiviral [9] and antibacterial activities [10]. We  have recently
synthesized a series of 3-styrylchromone derivatives, with
antioxidant and -glycosidase inhibition activities [11], and
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Table 1
Cytotoxicity of 3-styrylchromones against human oral squamous cell carcinoma and various oral normal cells. The data of Ca9-22, HSC-2, HSC-3, HSC-4, HGF, HPLF and HPC
were  cited from Ref. [12].
3-Styrylchromones Positive controls
Target cells [4] [6] [11] Doxorubicin 5-FU
Human oral squamous cell carcinoma 50% cytotoxic concentration (CC50) (M)
Derived from gingiva (Ca9-22) A 4.4 10 2.1 0.26 29
Derived from tongue (HSC-2) 4.4 6.8 1.0 0.12 13
Derived from tongue (HSC-3) 7.7 21 3.6 0.11 16
Derived from tonuge (HSC-4) 9.2 13 1.2 0.094 13
Average (mean ± S.D.) B 6.4 ± 2.4 13 ± 6.1 2.0 ± 1.2 0.15 ± 0.077 18 ± 7.6
Human  norml oral cells
Gingival ﬁbroblast (HGF) (C) C 229 544 67 0.87 >1000
Periodonal ligament ﬁbroblast (HPLF) 150 190 74 0.87 >1000
Pupl  cell (HPC) 396 284 272 >10 >1000
Average (mean) D 258 ± 126 339 ± 183 138 ± 116 >3.9 ± 5.3 >1000
Oral  keratinocyte (HOK) E 70 77 19 1.31 24.7
Primary gingival epithelial cell (HGEP) F 178 610 >800 0.027 18.8
Tumor-speciﬁcity index (TS)
D/B 40.3 26.1 69.0 >26.0 >55.6
C/A  52.0 54.4 31.9 3.3 >34.5
E/B  10.9 5.9 9.5 8.7 1.4
F/B  27.8 46.9 >400 0.2 1.0
PSE  = TS × (1/B) × 100
D/B2 630 
E/B2 170 
F/B2 434 
(E)-6-Methoxy-3-(4-methoxystyryl)-4H-chro men -4-one [4] 
(E)-6-Methoxy-3-(3,4,5 -trim ethoxystyryl)-4H-chromen-4-on e [6] 
(E)-3-(4-Hydro xystyryl)-6-met hoxy-4H-chro men -4-one [11] 
Fig. 1. Structure of (E)-6-methoxy-3-(4-methoxystyryl)-4H-chromen-4-one (com-
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tound 4), (E)-6-methoxy-3-(3,4,5-trimethoxystyryl)-4H-chromen-4-one (com-
ound 6) and (E)-3-(4-hydroxystyryl)-6-methoxy-4H -chromen-4-one (compound
1).
eported tumor-speciﬁc cytotoxicity [12]. Among ﬁfteen 3-
tyrylchromones, three new synthetic compounds that have
 methoxy group at 6-position of the chromone ring, (E)-3-
4-hydroxystyryl)-6-methoxy-4H-chromen-4-one (compound
1), (E)-6-methoxy-3-(4-methoxystyryl)-4H-chromen-4-one
compound 4), (E)-6-methoxy-3-(3,4,5-trimethoxystyryl)-4H-
hromen-4-one (compound 6) (Fig. 1) showed much higher
ytotoxicities against four human oral squamous cell lines [Ca9-22
derived from gingiva), HSC-2, HSC-3, and HSC-4 (derived from
ongue)] than against human normal oral mesenchymal cells200 3450 >17333 >309
45 475 5800 7.8
361 >20000 133 5.6
[gingival ﬁbroblast (HGF), periodontal ligament ﬁbroblast (HPLF),
and pulp cell (HPC)] (cited from Ref. [12] and shown in the upper
part of Table 1). The tumor-speciﬁcity (TS), determined as the ratio
of mean CC50 for human normal cells to that for human oral squa-
mous cell carcinoma cell (D/B in Table 1) (TS = 40.3, 26.1, 69.0) was
comparable with that for popular anti-cancer drugs, doxorubicin
and 5-FU (TS >26, >55.6). 3-Styrylchromones (compounds 4, 6, 11)
and 5-FU showed much higher cytotoxicity against Ca9-22 cells
than HGF cells (both derived from gingival tissues), giving higher
TS values as compared with doxorubicin (52.0, 54.4, 31.9, >34.5 vs.
3.3) (C/A in Table 1). However, these normal cells were derived
from mesenchymal tissues, different from epithelial tissue-derived
OSCC cell lines.
In the present study, we  ﬁrst investigated the cytotoxicity of
these synthetic compounds 4, 6, 11 against epithelial human oral
keratinocyte (HOK) and primary human gingival epithelial cells
(HGEP) to conﬁrm their tumor-speciﬁcity. We  then determined the
minimum treatment time required for cytotoxicity induction by the
most active compound 11 in a sensitive human OSCC cell line HSC-
2. Metabolomics, the measurement of all intracellular metabolites,
has become a powerful tool to gain insight into cellular function and
site of action. Therefore, using this technology, we ﬁnally investi-
gated possible changes in ﬁne cell structure and type of cell death,
and metabolic proﬁles induced by compound 11.
2. Materials and method
2.1. Materials
The following chemicals and reagents were obtained from
the indicated companies: Dulbecco’s modiﬁed Eagle’s medium
(DMEM), from GIBCO BRL, Grand Island, NY, USA; fetal bovine
serum (FBS), doxorubicin, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), tetraethylammonium
chloride (TEM) from Sigma–Aldrich Inc., St. Louis, MO,  USA;
dimethyl sulfoxide (DMSO), cycloheximide from Wako Pure Chem.
Ind., Osaka, Japan; 5-ﬂuorouracil (5-FU) from Kyowa, Tokyo, Japan;
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ulture plastic dishes and plates (96-well) were purchased from
ecton Dickinson (Franklin Lakes, NJ, USA).
.2. Synthesis of test compounds
(E)-6-Methoxy-3-(4-methoxystyryl)-4H-chromen-4-one
compound 4), (E)-6-methoxy-3-(3,4,5-trimethoxystyryl)-
H-chromen-4-one (compound 6) and
E)-3-(4-hydroxystyryl)-6-methoxy-4H-chromen-4-one (com-
ound 11)  (Fig. 1) were synthesized by Knoevenagel condensation
f the appropriate 3-formylchromone with selected phenylacetic
cid derivatives, as described previously [11]. All compounds were
haracterized by 1H NMR, MS  spectra and elemental analyses after
uriﬁcation by silica gel column chromatography and recrystal-
ization. All compounds were dissolved in DMSO at 80 mM and
tored at –20 ◦C before use.
.3. Cell culture
Human oral normal cells, gingival ﬁbroblast (HGF), periodon-
al ligament ﬁbroblast (HPLF) and pulp cell (HPC), established
rom the ﬁrst premolar tooth extracted from the lower jaw of a
2-year-old girl [13], and OSCC cell lines (Ca9-22, HSC-2, HSC-3,
SC-4), purchased from Riken Cell Bank, Tsukuba, Japan were cul-
ured at 37 ◦C in DMEM supplemented with 10% heat-inactivated
BS, 100 units/ml, penicillin G and 100 g/ml streptomycin sulfate
nder a humidiﬁed 5% CO2 atmosphere. Human oral keratinocytes
HOK) (purchased from COSMO BIO Co./Ltd., Tokyo) was cultured
n keratinocyte growth supplement (OKGS, Cat, No. 2652). Primary
uman gingival epithelial cells (HGEP) (purchased from CELLnTEC
dvanced Cell Systems AG, Bern, Switzerland) was growing in CnT-
R medium. Cells were then harvested by treatment with 0.25%
rypsin-0.025% EDTA-2Na in PBS(−) and either subcultured or used
or experiments.
.4. Assay for cytotoxic activity
Cells were inoculated at 2.5 × 103 cells/0.1 ml  in a 96-microwell
late. After 48 h, the medium was removed by suction with an
spirator and replaced with 0.1 ml  of fresh medium containing
ifferent concentrations of compound 4, 6 or 11,  or vehicles that
ontained the same amounts of DMSO without sample (as control).
sually, DMSO concentration was below 0.0125%. Cells were incu-
ated for the indicated times, and the relative viable cell number
as then determined by the MTT  method. In brief, the treated cells
ere incubated for another 3 h in fresh culture medium contain-
ng 0.2 mg/ml  MTT. Cells were then lysed with 0.1 ml  of DMSO and
he absorbance at 540 nm of the cell lysate was determined using a
icroplate reader (Biochromatic Labsystem, Helsinki, Finland). The
C50 was determined from the dose–response curve.
.5. Fine cell structure
HSC-2 cells were inoculated at 5 × 105 cells/10 ml  in 10 cm
ishes and incubated for 3 h. After medium change, near con-
uent cells were treated for 3 h with 0 (control), 3 or 10 M
f compound 11.  After washing three times with 5 ml  of cold
BS(−), the cells were ﬁxed for 1 h with 2% glutaraldehyde in
.1 M cacodylate buffer (pH 7.4) at 4 ◦C. The cells were scraped
ith a rubber policemen, pelleted by centrifugation, post-ﬁxed for
0 min  with 1% osmium tetraoxide-0.1 M cacodylate buffer (pH
.4), dehydrated and embedded in Araldite M (CIBA-GEIGY Swiss;
ISSHIN EN Co., Ltd., Tokyo, Japan). Thin sections were stained with
ranyl acetate and lead citrate, and were then observed under a
EM-1210 transmission electron microscope, Japan Electron Opticsports 2 (2015) 1281–1290 1283
Laboratory (JEOL, Co., Ltd., Akishima, Tokyo, Japan) (magniﬁcation:
×5000) at an accelerating voltage of 100 kV [14].
2.6. Western blot analysis
HSC-2 cells were washed in ice-cold PBS and then whole
cell lysates were prepared using laemmli sample buffer. Whole
cell lysates (5 × 104 cells per lane) were separated by 12% SDS-
polyacrylamide gel electrophoresis, and blotted onto a PVDF
membrane (Merck Millipore, Darmstadt, Germany). The membrane
was then blocked against non-speciﬁc binding by treatment for
1 h with 5% bovine serum albumin in Tris-buffered saline (pH 7.6)
containing 0.1% Tween 20, and then immunoblotted overnight at
4 ◦C using the respective primary antibody. Next, the membrane
was incubated for 1 h at room temperature with a horseradish
peroxidase-conjugated anti-rabbit IgG secondary antibody, and the
protein bands were visualized using an immobilon Western Chemi-
luminescent HRP Substrate (Merck Millipore). Protein expression
was quantiﬁed using ChemiDoc MP  imaging system (Bio-Rad,
Hercules, CA, USA). The following antibodies were used: anti-
PARP, anti-caspase 3 antibodies (1:1000, Cell Signaling Technology,
Danvers, MA,  USA), anti-LC3 antibody (1:1000, Medical & Biologi-
cal Laboratories, Nagoya, Japan), anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) antibody (1:20,000, Trevigen, Helger-
man, Gaithersburg, MD,  USA), and anti-rabbit IgG horseradish
peroxidase-linked whole antibody (1:20,000, GE Healthcare, Little
Chalfont, Buckinghamshire, England).
2.7. Processing for metabolomic analysis
HSC-2 cells were inoculated at 5 × 105 cells/10 ml in 10 cm
dishes and incubated for 48 h. The medium was  replaced with fresh
medium and the cells were incubated for 30 min  at 37 ◦C in a 5%
CO2 incubator to stabilize the pH and temperature of the culture
medium. The cells were treated for 3 h with 0 (control), 1, 3 and
10 M of compound 11.  Aliquots of the cells were trypsinized for
counting the viable cell number with hemocytometer after staining
with trypan blue. The remaining cells were washed twice with 5 ml
of ice cold 5 % d-mannitol solution and then immersed for 10 min
in 1 ml  of methanol containing internal standards (25 M each of
methionine sulfone, 2-[N-morpholino]-ethanesulfonic acid and d-
camphor-10-sulfonic acid). Cold 5% d-mannitol solution was used
to minimize the leak of intracellular metabolites during the wash-
ing process, and metabolites were directly extracted with methanol
from the attached cells, since detachment of the cells by trypsin
resulted in a signiﬁcant loss of intracellular metabolites [15], and
scraping off the cells by a rubber policeman caused 5–10% of cell
death (unpublished data). We  conﬁrmed that only a few percent
of lactate was solubilized from the blank samples in plastic by
chloroform treatment, indicating the cross-contamination within
the extraction procedure was  very little [16], and this blank was
subtracted from all samples. The methanol extract (supernatant)
was collected. To 400 l of the dissolved samples, 400 l of chlo-
roform and 200 l of Milli-Q water were added and the mixture
was centrifuged at 10,000 × g, for 3 min  at 4 ◦C. The aqueous layer
was ﬁltered to remove large molecules by centrifugation through
a 5 kDa cut-off ﬁlter (Millipore, Billerica, MA)  at 9100 × g for 3.0 h
at 4 ◦C. The 320 l of the ﬁltrate was  concentrated by centrifuga-
tion and dissolved in 50 l of Milli-Q water containing reference
compounds (200 M each of 3-aminopyrrolidine and trimesate)
immediately before CE-TOFMS analysis [15–18].
All samples were quantiﬁed using one-time batch measure-
ment. The sensitivity ﬂuctuation derived from mass spectrometry
was corrected by internal standards added to each sample.
However, we  also conﬁrmed the consistency of the sensi-
tivity among all samples measured in this study, since the
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Fig. 2. Time course of cytotoxicity induction by (E)-6-methoxy-3-(4-methoxystyryl)-4H-chromen-4-one (compound 4), (E)-6-methoxy-3-(3,4,5-trimethoxystyryl)-4H-
chromen-4-one (compound 6) and (E)-3-(4-hydroxystyryl)-6-methoxy-4H-chromen-4-one (compound 11). HSC-2 cells were incubated for the indicated times, and medium
was  replaced with fresh medium and incubated further until 47 h after the initial addition of samples. The relative viable cell number was then determined by the MTT
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eak areas of the internal standards were nearly constant in
ll measurements. Data of intracellular concentration of each
etabolite was presented after normalization by cell count. A
argeted assay that detects the peaks at the sample place with
ommercially available samples [19] was used in the present
tudy.
.8. Instrument parameters for metabolomic analysis
The instrumentation and measurement conditions used for CE-
OF-MS were described elsewhere [20,21] with slight modiﬁcation
18]. We  used the capillary electrophoresis (CE) among various
ypes of separation systems available for metabolomics proﬁling,
ince this method is quantitative, sensitive, and robust, and its
tility was demonstrated in the analysis of broader primary path-
ays whose most metabolites were electronically charged [22],
s compared with conventional liquid chromatography (LC) or gas
hromatography (GS) that required repeated running due to their
arrow analysis range. Cation analysis was performed using ans. The difference between control and treated group that shows less than 80% of
imilar results. The 50% cytotoxic concentration (CC50) was calculated and listed in
Agilent CE capillary electrophoresis system, an Agilent G6220A
LC/MSD TOF system, an Agilent 1100 series isocratic HPLC pump,
a G1603A Agilent CEMS adapter kit, and a G1607A Agilent CE-
ESI-MS sprayer kit (Agilent Technologies, Waldbronn, Germany).
Anion analysis was performed using an Agilent CE capillary elec-
trophoresis system, an Agilent G1969A LC/MSD TOF system, an
Agilent 1200 series isocratic HPLC pump, a G1603A Agilent CE-MS
adapter kit, and a G7100A Agilent CE-electrospray ionization (ESI)
source-MS sprayer kit (Agilent Technologies). For the cation and
anion analyses, the CE-MS adapter kit included a capillary cassette
that facilitates thermostatic control of the capillary. The CE-ESI-MS
sprayer kit simpliﬁes coupling of the CE system with the MS  system
and is equipped with an electrospray source. For system control and
data acquisition, 3D-CE ChemStation software (Rev. B.04.01.SP1)
was used for CE. Agilent MassHunter software (B.02.00, B1128.5)
and AnalystQS (ver.1.1 Build 9865, Applied Biosystems, Foster, CA)
were used for TOF-MS. The original Agilent SST316Ti stainless steel
ESI needle was replaced with a passivated SST316Ti stainless steel
and platinum needle (passivated with 1% formic acid and a 20%
H. Sakagami et al. / Toxicology Reports 2 (2015) 1281–1290 1285
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Hig. 3. Induction of mitochondrial vacuolization by compound 11.  Cells were treat
 ml  of cold PBS(−), the cells were ﬁxed for 1 h with 2% glutaraldehyde and the ﬁne
queous solution of isopropanol at 80 ◦C for 30 min) for anion anal-
sis.
.8.1. Cationic metabolite analysis
For cationic metabolite analysis using CE-TOFMS, sample sepa-
ation was performed in fused silica capillaries (50 m i.d. ×100 cm
otal length) ﬁlled with 1 M formic acid as the reference electrolyte.
he capillary was ﬂushed with formic acid (1 M)  for 20 min  before
he ﬁrst use and for 4 min  before each sample injection. Sample
olutions (approximately 3 nl) were injected at 50 mbar for 5 s and
 voltage of 30 kV (constant voltage) was applied. The capillary
emperature was maintained at 20 ◦C and the temperature of the
ample tray was kept below 5 ◦C. The sheath liquid, composed of
ethanol/water (50% v/v) and 0.1 M hexakis(2,2-diﬂuoroethoxy)
hosphazene (Hexakis), was delivered at 10 l/min. ESI-TOF-MS
as conducted in the positive ion mode. The capillary voltage was
et at 4 kV and the ﬂow rate of nitrogen gas (heater tempera-
ure = 300 ◦C) was set at 7 psig. In TOF-MS, the fragmentor, skimmer
nd OCT RF voltages were 75, 50 and 125 V, respectively. Automatic
ecalibration of each acquired spectrum was performed using ref-
rence standards ([13C isotopic ion of protonated methanol dimer
2MeOH + H)]+, m/z 66.0631) and ([protonated Hexakis (M + H)]+,
/z 622.0290). Mass spectra were acquired at a rate of 1.5 cycles/s
ver a m/z  range of 50–1000.
.8.2. Anionic metabolite analysis
For anionic metabolite analysis using CE-TOF-MS, a com-
ercially available COSMO(+) capillary (50 m × 105 cm,  Nacalai
esque, Kyoto, Japan), chemically coated with a cationic polymer,
as used for separation. Ammonium acetate solution (50 mM;  pH
.5) was used as the electrolyte for separation. Before the ﬁrst
se, the new capillary was ﬂushed successively with the running
lectrolyte (pH 8.5), 50 mM acetic acid (pH 3.4), and then the elec-
rolyte again for 10 min  each. Before each injection, the capillary
as equilibrated for 2 min  by ﬂushing with the acetic acid again
nd then with the running electrolyte for 5 min. A sample solu-
ion (approximately 30 nl) was injected at 50 mbar for 30 s, and
 voltage of −30 kV was applied. The capillary temperature was
aintained at 20 ◦C and the sample tray was cooled below 5 ◦C.
n Agilent 1100 series pump equipped with a 1:100 splitter was
sed to deliver 10 l/min of 5 mM ammonium acetate in 50% (v/v)
ethanol/water, containing 0.1 M Hexakis, to the CE interface.
ere, it was used as a sheath liquid surrounding the CE capillary 3 h with 0 (control), 3 or 10 M of compound 11.  After washing three times with
tructures were observed under TEM.
to provide a stable electrical connection between the tip of the
capillary and the grounded electrospray needle. ESI-TOF-MS was
conducted in the negative ionization mode at a capillary voltage of
3.5 kV. For TOF-MS, the fragmentor, skimmer and OCT RF voltages
were set at 100, 50 and 200 V, respectively. The ﬂow rate of the
drying nitrogen gas (heater temperature = 300 ◦C) was  maintained
at 7 psig. Automatic recalibration of each acquired spectrum was
performed using reference standards ([13C isotopic ion of depro-
tonated acetic acid dimer (2CH3COOH − H)]−, m/z 120.03841),
and ([Hexakis deprotonated acetic acid (M + CH3COOH − H)]−, m/z
680.03554). Exact mass data were acquired at a rate of 1.5 spectra/s
over a m/z range of 50–1000.
2.9. Statistical analysis
Data are expressed as the mean ± standard deviation (SD). Sta-
tistical analysis was  performed by paired t-test. Differences were
considered signiﬁcant at p < 0.05. Raw data of metabolomics anal-
ysis were analyzed using our proprietary software, MasterHands
[23]. The processing ﬂow used in this software was the noise-
ﬁltering, baseline correction, peak detection and integration of the
peak area from sliced electropherograms (the width of each elec-
tropherogram was  0.02 m/z), elimination of noise and redundant
features, and generation of an aligned data matrix with annotated
metabolite identities and relative areas (peak areas normalized to
those of internal standards) [24].
Concentrations were calculated using external standards based
on relative area, i.e., the area divided by the area of the internal
standards. Overall metabolomic proﬁles were accessed by princi-
pal component (PC) analysis (PCA) (Supplementary Figs. 1S and
2S). XLstat (Ver. 2014.1.04, Addinsoft, Paris, France) and GraphPad
Prism (Ver 5.04, GraphPad Software, San Diego, CA) were used for
PCA and other statistical tests. p-values calculated for metabolomic
data were corrected by false discovery rate (FDR), accommodat-
ing multiple independent tests using R package (Ver. 3.0.2., http://
www.r-project.org/) and corrected p < 0.05 was considered signif-
icant. FDR (such as Q-value) was  introduced as an indicator that
shows to which extent the false positive is approved, since p-value
alone produce many false positive due to multiple independent
statistical tests for evaluating metabolomics data.
Internal standards were added to both test and standard
samples to eliminate the systematic bias and absolute quantita-
tion was performed by 1-point calibration curve using external
1 ogy Reports 2 (2015) 1281–1290
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Table 2
Time course of cytotoxicity induction by compounds 4, 6 and 11.  HSC-2 cells were
exposed for the indicated times with various concentrations of compound 4, 6 or
11,  replaced with fresh culture medium without sample, and incubated until 47 h
after addition of sample. The 50% cytotoxic concentration (CC50) was  determined
from the dose–response curve described in Fig. 2.
CC50 (M)
Exposure time (h) [4] [6] [11]
Exp. I
1 61 65 18
3  20 45 10
6.7  21 50 9.5
21  2.5 5.1 <1.56
31  2.4 4.5 <1.56
47  2.4 4.6 <1.56
Exp. II
1 41 42 14
3  19 19 5.9
7  20 20 5.5
23  2.6 4.2 <0.39
31  3.9 4.7 <0.39
47  4.3 2.2 <0.39
Fig. 4. Biological feature of compound 11-induced cell death. A. Detection of the
apoptotic marker, cleaved PARP1 and caspase-3, and the autophagic marker, LC3 in
compound 11-induced cell death. Cells were treated with or without 10 M com-
pound 11 for indicated time, and the cell lysates were analyzed by western blotting
using anti-PARP, anti-caspase 3, anti-LC3, and anti-GAPDH antibodies. The expres-286 H. Sakagami et al. / Toxicol
tandards. Since injection volume of sample to CE was  extremely
mall (approximately 3 nl) as compared with LC, we  used 1-point
alibration that keeps the linearity with negligible incidence of ion-
uppression [22,25].
. Results
.1. Tumor-speciﬁcity
3-Styrylchromones (compounds 4, 6, 11)  showed weak cyto-
oxicity against human oral keratinocyte (HOK) (CC50 = 70, 77 and
9 M)  (E) and primary human gingival epithelial cells (HGEP)
CC50 = 178, 610 and >800 M)  (F), as compared with human OSCC
ell lines (mean CC50 = 6.4, 13 and 2.0 M)  (B), yielding the tumor-
peciﬁcity (TS) value of 10.9, 5.9, and 9.5 (E/B), and 27.8, 46.9
nd >400 (F/B), respectively (Table 1). On the other hand, dox-
rubicin and 5-FU showed much higher cytotoxicities against
oth HOK (CC50 = 1.31 and 24.7 M,  respectively) (E) and HGEP
ells (CC50 = 0.027 and 18.8 M,  respectively) (F), yielding very
ow tumor-speciﬁcities (1.4–8.7) (E/B) and (0.2–1.0) (F/B), respec-
ively (Table 1). Taken together, these results demonstrated that
-styrylchromones (compounds 4, 6, 11)  showed higher tumor-
peciﬁcity, regardless of the type of normal cells: either epithelial
r mesenchymal origin.
In order to identify which compounds have both good potency
nd selective toxicity to neoplasms, the potency-selectivity expres-
ion (PSE) values of the compounds were calculated. This property
s the product of the reciprocal of the average CC50 value and the
verage TS ﬁgure multiplied by 100 [26]. When HGF/HPLF/HPC
as used as normal cells, doxorubicin showed the highest PSE
alue (>17,333), followed by compound 11 (3450) > 4 (630) > 5-
U (>309) > 6 (200) (D/B2 in Table 1). When HOK cells were
sed as normal cells, doxorubicin showed the highest PSE value
5800), followed by compound 11 (475) > 4 (170) > 6 (45) > 5-FU
7.8) (E/B2 in Table 1). When HGEP cells were used as normal
ells, compound 11 showed the highest PSE value (>20,000), fol-
owed by 4 (434) > 6 (361) > doxorubicin (133) > 5-FU (5.6) (F/B2 in
able 1). These results showed that compound 11 has the high-
st potency and selective toxicity to neoplasms among these three
-styrylchromones.
.2. Time-course of cytotoxicity induction
We  next performed the pulse-chase experiments with 3-
tyrylchromones to determine the minimum treatment time
equired for cytotoxicity induction. HSC-2 cells were treated for
arious times with increasing concentrations of compound 4, 6
r 11,  and then cultured in drug-free medium until 47 h after
reatment to determine the viable cell number. The magnitude
f cytotoxicity induction by these drugs increased with treatment
ime up to 21 h (Exp. I in Table 2). Close inspection of the time
inetics demonstrated two plateaus of CC50 value at 3–6.7 h and
1–47 h after exposure. Repeated experiments reproduced simi-
ar results with two plateaus of CC50 value at 3–7 h and 23–47 h
Exp. II in Table 2). Compound 11 showed the highest cytotox-
city [CC50 = <1.56 M (Exp. I); <0.39 M (Exp. II)], followed by
ompound 4 [CC50 = 2.5 M (Exp.I); 2.6 M (Exp. II)] and then com-
ound 6 [CC50 = 5.1 M (EXP. I); 4.2 M (Exp. II)] (Table 1). The
rders of cytotoxicity potencies of these 3 compounds were the
ame with that of our previous data [12]. It was unexpected that
igher concentrations of compounds 4, 11 were cytotoxic, produc-
ng more than 90% dead cells, whereas compound 6 was rather
ytostatic, leaving 30% viable cells (Fig. 2). These data suggest that
he cytotoxicity was triggered as early as 3 h after treatment withsion of GAPDH was  used as an internal control. Density of full-length PARP1 and
cleaved caspase-3 proteins is represented by the ratio of full-length PARP1/GAPDH
or  cleaved caspase-3/GAPDH protein band in each time points.
compound 11,  and 11 showed the highest cytotoxicity and tumor-
speciﬁcity among three 3-styrylchromones.
3.3. Effect on ﬁne cell structure
We  next investigated the possible intracellular changes during
early stages of cell cytotoxicity induction. When HSC-2 cells were
treated for 3 h with 3 (B) or 10 (C) M of compound 11,  mitochon-
drial vacuolization became prominent as compared with control
cells (A) (Fig. 3), suggesting the induction of mitochondrial injury.
3.4. Type of cell death induced by compound 11
We  investigated what type of cell death induced by compound
11 in HSC-2 cells, using cleavage of PARP1 and caspase-3, as apopto-
sis marker [27] and LC3 as autophagy marker [28] (Fig. 4). Untreated
HSC-2 cells expressed higher levels of LC3-II than LC3-I, suggesting
constitutional expression of autophagy marker (lane 1). When HSC-
2 cells were incubated for 4, 7.5 and 23 h with 10 M compound 11,
H. Sakagami et al. / Toxicology Reports 2 (2015) 1281–1290 1287
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1ig. 5. Heat-map and bar graph visualization of the quantiﬁed metabolites. Heatmap
f  metabolites in 0, 1, 3 or 10 M of compound 11-treated cells. Q value is a p value
eader  is referred to the web  version of this article.)
he LC3-II expression decreased time-dependently to undetectable
evel (lane 2–4). This was  paralleled with the loss of full length PARP
t 23 h after treatment and the appearance of cleaved PARP1 and
aspase-3 by limited digestion (lane 4). These results indicate that
he treatment of compound 11 induced apoptotic cell death after
uppression of autophagy.
It has recently been reported that benfotiamine induced para-
tosis [characterized by cytoplasmic vacuolization and sensitivity
o speciﬁc BH channel blocker (tetraethylammonium)] in leukemia
ells without induction of apoptosis nor autophagy [29]. Therefore,
here was a possibility that compound 11,  that induce mitochon-
rial vacuolization (Fig. 3), may  induce paraptosis. This possibility,
owever, seems to be low, since we found that the cytotoxicity of
1 was not inhibited by BH blocker (tetraethylammonium) (Sup-
lementary Fig. 3).
.5. Effect on metabolomic proﬁles
HSC-2 cells were incubated for 3 h with 0 (control), 1, 3 or 10 M
ompound 11 and intracellular metabolites were extracted with
ethanol and subjected to metabolomics analysis. A total of 119
etabolites were detected, and among that, 22 metabolites showed
igniﬁcant changes (Fig. 5). We  identiﬁed these metabolites using
tandard mixtures. We  conﬁrmed that the corrected migration
ime, m/z  value and distribution of isotopic peaks of each metabolite
ere identical with those of standard mixtures. We  also performed
pike test that conﬁrmed that the addition of standard mixture to
ach sample resulted in the increase of peak that corresponds with
ach standard component.
Treatment of compound 11 did not signiﬁcantly affect the
ntracellular concentration of metabolites in TCA cycle (citrate, cis-
coniate, succinate, fumarate, malate) (minor reduction), glycolytic
etabolites (glucose-6-phosphate, fructose 6-phosphate, fructose
,6-bisphospate, 3-phosphoglyceric acid) (minor increase), lactateing the quantiﬁed metabolites using a white–blue–red scheme, and the fold-change
cted by FDR. (For interpretation of the references to color in this ﬁgure legend, the
(minor reduction), urea cycle (citrullin, arginine, ornithine) (no
change or minor reduction) and polyamine pathway (putrescine,
spermidine) (minor reduction) and the ratios of AMP/ATP (minor
reduction), GMP/GTP (minor reduction) and NADH/NAD+ ratio
(minor increase) (Supplementary Table 1). We could not observe
any signiﬁcance to pathways/cycles/ratios, possibly due to the fact
that metabolomics assay was  performed at much earlier stages
after treatment with compound 11 when apoptosis induction
was not detected. Tracer experiments with precursor metabolites
labeled with stable isotope are necessary to identify the target path-
ways/metabolites.
On the other hand, intracellular concentrations of 4-methyl-2-
oxopentanoate, 2-hyroxyglutarate, creatine, 2-oxoisopentanoate
(Q < 0.2), glycine (Gly) and choline (p < 0.05) were signiﬁcantly
reduced (Fig. 6A). 2-Oxogltarate was  also reduced, but not signiﬁ-
cantly.
Intracellular concentrations of proline (Pro), asparagine (Asn),
dihydroxyacetone phosphate (DHAP), ribulose 5 phosphate
(Ru5P), transcinnamate, -butyrobetaine (Q < 0.2) and glutamic
acid (Glu) (p < 0.05) were signiﬁcantly increased (Fig. 6B).
Diethanolamine and cytidine diphosphate-choline (CDP-choline)
were also increased, but not signiﬁcantly.
4. Discussion
The present study demonstrated that compound 11,  the most
cytotoxic compound among three 3-styrylchromones, showed
the highest tumor-speciﬁcity (TS = 9.5, >400), based on higher
cytotoxicity against human OSCC cell lines, as compared with
human epithelial normal oral cells HOK (TS = 9.5) and HGPE
(TS > 400) (Table 1). It was  unexpected that doxorubicin and 5-
FU were extremely cytotoxic to HOK (TS = 1.4–8.7) and HGEP
(TS = 0.2–1.0), giving disappointedly lower tumor selectivity. This
may  be resulted from the higher enhanced DNA replication
1288 H. Sakagami et al. / Toxicology Reports 2 (2015) 1281–1290
Fig. 6. Effects of compound 11 on various cellular compounds. HSC-2 cells were treated for 3 h with 0 (control), 1, 3 and 10 M of compound 11,  and intracellular concentra-
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tions  of 4-methyl-2-oxopentanoate, 2-hydroxyglutarate, creatine, 2-oxoisopentano
Asn),  dihydroxyacetone phosphate (DHAP), ribulose 5 phosphate (Ru5P), trans-cin
etermined by metabolomics analysis. Each value represents mean ± S.D. of quadru
ctivities of HOK and HGEP cells by growth factor-enriched
edium, supplied by manufacturers. Although the cytotoxic-
ty of doxorubicin may  be partially reduced by stimulating the
asal mitochondrial respiration [30], special care should be taken
or oral application of these antineoplastic agents. Since com-
ound 11 had comparable hydrophobic property (log P = 3.10)
ith doxorubicin (log P = 2.82), the higher tumor-speciﬁcity of 3-
tyrylchromones cannot simply be explained by its hydrophobic
roperty.
We  next investigated what are the earliest intracellular changes
nduced by compound 11.  The pulse-chase experiments revealed
hat 3 h-treatment time with compound 11 committed the cells
nto the ﬁrst wave of cell death pathway (Table 2). TEM showed that
ompound 11 dose-dependently induced mitochondrial vacuoliza-
ion, suggesting the mitochondrial injury at early stage of cell death
nduction. Interestingly, Western blot analysis revealed that HSC-2
ells constitutionally expressed higher level of autophagy marker
C3-II, and treatment of compound 11 initially induced the loss
f autophagy marker, followed by appearance of apoptosis marker
cleaved PARP1 and caspase-3) at later stage (Fig. 4). These data sug-
est that the initial reduction of autophagy, which that is involved
n cell survival, triggered apoptosis. Constitutional expression of
C3-II in HSC-2 cells may  explain why many anticancer agents,
uch as doxorubicin [31], mitomycin C [32], geﬁtinib in combina-
ion with docetaxel [33], were hard to induce typical apoptosis in
his cell line.acetylcarnitine, glycine (Gly), 2-oxoglutarate, choline (A), proline (Pro), asparagine
e, -butyrobetaine, glutamic acid (Glu), diethanolamine and CDP-choline (B) were
e assays. Q value is a p value corrected by FDR.
Metabolomic analysis demonstrated that compound 11 did
not signiﬁcantly affect major cellular metabolic pathways such
as TCA cycle, glycolysis, urea and polyamine pathways, nor
effected the ATP and GTP utilization. Compound 11,  however,
signiﬁcantly reduced the intracellular concentrations of 4-methyl-
2-oxopentanoate and 2-oxoisopentanoate that are the degradation
products of leucine and valine (catalyzed by branched-chain-
amino acid amino transferease EC2.6.1.42), respectively (Fig. 6A).
Compound 11 also reduced the intracellular concentrations of
2-hydroxyglutarate and creatine, possibly due to the decline of 2-
oxoglutarate (catalyzed by 2-hydroxyglutarate dehydrogenase EC
1.1.99.2) and glycine (Gly) (catalyzed by arginine glycine amidino-
transferase EC2.1.4.1 and guanidinoacetate N-methyltransferase
EC2.1.2.1), respectively. On the other hand, Compound 11 signif-
icantly increased the intracellular concentrations of proline (Pro),
asparagine (Asn), dihydroxyacetone phosphate (DHAP), ribulose 5
phosphate (Ru5P), transcinnamate, -butyrobetaine and glutamic
acid (Glu) (Fig. 6B). It should be noted that the only amino acid sig-
niﬁcantly changed were Pro, Gly, and Asn. We  have recently found
that salivary concentrations of Gly and Pro were age-dependently
increased keeping the constant ratio of Gly to Pro [34] (Sugimoto
et al; unpublished data). However, biological signiﬁcance of these
changes is not clear at present.
We  also found that compound 11 dramatically but not signiﬁ-
cantly increased the intracellular concentration of diethanolamine.
Large standard deviation of intracellular levels of diethanolamine
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iminished the statistical signiﬁcance. This suggests the rapid
urnover of this compound, rather the experimental artifacts. As
ar as we know, the cytotoxicity of diethanolamine have not
een well investigated, and most of previous studies have lim-
ted to non-human creatures such as aquatic biota [35]. Treatment
f cultured mouse neural precursor cells with diethanolamine
educed the intracellular uptake and accumulation of choline [36].
hen pregnant mice were treated dermally with diethanolamine,
poptosis was induced in the hippocampal ventricular zone of
he brain of fetuses [37]. This agrees with the present ﬁnd-
ng that compound 11 increased the intracellular levels of
iethanolamine and CDP-choline (Fig. 6B) and reduced that of
holine (Fig. 6A). This suggests that compound 11 down-regulate
he glycerophospholipid pathway. The relatively higher lipophilic
roperty of diethanolamine (log P = 1.761) suggests its interaction
ith lipophilic membrane components. Since the extracellular
oncentration of diethanolamine was not apparently changed
efore and after treatment with compound 11 (12.1 ± 13.4 M and
1.8 ± 5.3 M,  respectively) (Supplementary Table S1), the increase
f diethanolamine should be the increase of its production, rather
han the entry from the medium. There are many factors that may
ffect the ﬂuctuations of diethanolamine level; type of cells and
nducers. During NaF-induced apoptosis-induction in HSC-2 cells,
e have found similar elevation of diethanolamine (our prelim-
nary observation). However, the connection of diethanolamine
nd apoptosis induction awaits more rigorous time course study.
urther studies are needed to elucidate the mechanism by which
ompound 11 increases diethanolamine level.
Our recent metabolomics analysis demonstrated that (i) apo-
tosis induction (characterized by caspase-3 activation, internu-
leosomal DNA fragmentation, enhanced BAD protein expression)
y NaF (5 mM,  4 h) in HSC-2 cells [38] was accompanied by rapid
ecline of glycolysis and TCA cycle progression and increase of
TP utilization (AMP/ATP ratio) and oxidative stress (elevated level
f GSSG/GSH ratio, methionine sulfoxide) [17], and (ii) necrosis-
nduction by eugenol (1.4 mM,  4 h) in HSC-2 cells was accompanied
y slight enhancement of glycolysis and oxidative stress without
pparent change in TCA cycle and ATP utilization [15], and (iii)
ecrosis-induction by eugenol (2 mM,  20 min) in human normal
ingival ﬁbroblast, periodontal ligament ﬁbroblast and pulp cells
as accompanied by rapid decline of TCA cycle without affecting
lycolysis (Sakagami et al., manuscript in preparation). These data
uggest possible connection between the apoptosis induction and
TP utilization, and that perturbation of glycolysis and TCA cycle,
nd oxidative stress are not speciﬁc for the type of cell death. On the
ther hand, we have not observed the increase of ATP utilization at
 h after treatment with compound 11,  when apoptosis induction
as not detected. Further time course study is essential to connect
TP utilization and apoptosis more accurately.
We found that pretreatment with cycloheximide inhibited the
ytotoxicity (Supplementary Fig. 3) and morphological changes
i.e., displaying round shape and detachment from the plastic plate)
data not shown) induced by compounds 4, 6 and 11,  suggesting
hat protein synthesis may  be required for cytotoxicity induction.
Compound 11 is not only a new compound that shows the high-
st TS and PSE values among three 3-styrylchromones, but also its
tructure can be modiﬁed by introduction of various substituent
roups at 5–7 position of chromone ring. Further studies are needed
o investigate whether such substituted compounds have higher
umor-speciﬁcity than the parent compound.
Our recent QSAR analysis of sixteen 3-styryl-2H-chromene
erivatives demonstrated that all derivatives showed relatively
igh tumor selectivity. Especially, compound that have a methoxy
roup at 7-position of the chromene ring and chlorine at 4′-
osition of phenyl group in styryl moiety showed the highest
umor-speciﬁcity (TS) and potency-selectivity expression (PSE) val-
[
[ports 2 (2015) 1281–1290 1289
ues, exceeding those of resveratrol, doxorubicin and 5-FU [39].
These data, combined with the present study, suggest the possible
antitumor potential of 3-styryl-4H-chromones and 3-styryl-2H-
chromenes.
Since at least 106 cells are required for each time point, no
one has succeeded to perform the metabolomic analysis at a time
point of the cell cycle, under strictly controlled conditions. If more
sensitive method would be established, cell cycle effects could be
accurately evaluated and subtracted.
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